Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NYSE:CUZ
NYSE:CUZOffice REITs

A Look At Cousins Properties (CUZ) Valuation After Recent Share Price Pullback

Why Cousins Properties is on investors’ radar Cousins Properties (CUZ) has attracted attention after a recent share price pullback, with the stock showing negative returns over the past month and past 3 months despite its established Sun Belt office portfolio. See our latest analysis for Cousins Properties. Over the past year, Cousins Properties has seen a 10.69% decline in total shareholder return, while the recent 7 day share price return of 5.25% hints at short term momentum building from...
NasdaqGS:HLIT
NasdaqGS:HLITCommunications

A Look At Harmonic (HLIT) Valuation After TDF Adopts Its AI‑Driven Broadcast Technology

Harmonic (HLIT) is back in focus after TDF, a major French broadcast infrastructure operator, upgraded its nationwide terrestrial network using Harmonic’s XOS and ProStream X platforms, spotlighting the company’s media processing capabilities. See our latest analysis for Harmonic. Despite the TDF and KBRO wins and new sports streaming features, Harmonic’s recent momentum has been mixed, with a 30 day share price return of a 7.35% decline contrasting with a 1 year total shareholder return of...
NYSE:AORT
NYSE:AORTMedical Equipment

Should Artivion’s Q4 Revenue Miss Amid Strong Product Growth Require Action From AORT Investors?

Artivion’s recent Q4 results showed revenue rising 19.2% year on year, driven by strong growth in stent grafts, On-X products, and preservation services, but coming in just 0.8% below analyst expectations. Despite delivering solid full-year 2025 adjusted revenue and EBITDA growth, Artivion’s relatively weaker performance versus peer estimates raises questions about how much near-term momentum investors should expect. Next, we’ll examine how this slight quarterly revenue miss, despite strong...
NasdaqGS:ROIV
NasdaqGS:ROIVBiotechs

Roivant Sciences (ROIV) Is Up 6.8% After Mixed Autoimmune Trial Updates - Has The Bull Case Changed?

In early April 2026, Roivant Sciences reported mixed clinical updates, including Priovant’s launch of a Phase 2b/3 brepocitinib trial in lichen planopilaris and Immunovant’s Phase 3 batoclimab thyroid eye disease studies not meeting their primary endpoint. The brepocitinib program now spans four late-stage indications and has Priority Review for dermatomyositis, underscoring Roivant’s emphasis on high-need autoimmune conditions despite setbacks for batoclimab. We’ll now examine how the...
NYSE:TEVA
NYSE:TEVAPharmaceuticals

How Investors Are Reacting To Teva (TEVA) Advancing Its Biosimilar Pipeline With New FDA and EMA Milestones

In late March 2026, Teva Pharmaceutical Industries reported three biosimilar milestones, including US FDA approval of PONLIMSI (denosumab-adet) as a biosimilar to Prolia for all its osteoporosis-related indications, alongside FDA and EMA acceptance of filings for a proposed Xolair (omalizumab) biosimilar across its full label. These advances highlight Teva’s effort to broaden its higher-value biopharmaceutical portfolio, using biosimilars to complement its generics base and support its Pivot...
XTRA:O5G
XTRA:O5GReal Estate

CPI Property Group (XTRA:O5G) Valuation Check After Return To Profit And Higher Occupancy

CPI Property Group (XTRA:O5G) just reported full year 2025 results, returning to a net profit of €185.6 million while revenue and sales softened, and occupancy reached 93% with €1.1b of property disposals completed. See our latest analysis for CPI Property Group. The latest earnings release and balance sheet moves appear to have steadied sentiment, with a 1.38% 1 day share price return. However, a 5.77% 90 day share price decline and a 9.82% 1 year total shareholder return decline suggest...
NYSE:WU
NYSE:WUDiversified Financial

Assessing Western Union (WU) Valuation After Jim Cramer Comments And Recent Share Price Move

Recent comments from television host Jim Cramer, who questioned Western Union (WU) as a growth idea despite its dividend appeal, have put the stock back in focus after a roughly 6.5% move higher. See our latest analysis for Western Union. The recent 6.5% share price move and 1 day share price return of 2.96% come against a weaker backdrop, with a 30 day share price return of 10.21% and a 1 year total shareholder return of 4.4% and 5 year total shareholder return of 49.31%. This suggests...
NasdaqGM:MIRM
NasdaqGM:MIRMBiotechs

Assessing Mirum Pharmaceuticals (MIRM) Valuation After Record Revenues First GAAP Profitability And Key Trial Milestones

Mirum Pharmaceuticals (MIRM) has drawn fresh attention after reporting record quarterly net product revenue, raising full year revenue guidance, achieving its first GAAP profitability, and completing enrollment in several key clinical trials. See our latest analysis for Mirum Pharmaceuticals. The recent clinical and regulatory milestones appear to have fed into strong momentum, with a 90 day share price return of 20.62% and a 1 year total shareholder return of 124.05%. The current share price...
NYSE:FCN
NYSE:FCNProfessional Services

Is FTI Consulting’s (FCN) New AI Governance Leader a Signal on Its Long-Term Tech Strategy?

In March 2026, FTI Consulting, Inc. appointed Kelly Henney as Senior Managing Director and Australia Leader of its Information Governance, Privacy & Security practice within the Technology segment, based in Sydney. Her background in artificial intelligence governance, data privacy, and digital risk, combined with legal and banking experience, enhances FTI’s ability to advise clients on complex regulatory and compliance challenges. Next, we’ll examine how Henney’s artificial intelligence...
NYSE:FLNG
NYSE:FLNGOil and Gas

How Investors May Respond To FLEX LNG (FLNG) Extending Flex Aurora Charter And Lifting Contract Backlog

In March 2026, Flex LNG Ltd. announced a new time charter for the Flex Aurora with a Supermajor, securing a firm two-year term plus optional extensions that could keep the vessel employed through 2034 and lift the company’s total contract backlog to a minimum of 55 years, or up to 82 years if all options are used. This incremental charter backlog adds further revenue visibility at a time when the company has flagged potential revisions to its full-year 2026 guidance amid volatile LNG...